Go Pro
NYSE:DVA

DaVita (DVA) Stock Price, News & Analysis

DaVita logo
$180.14 +0.97 (+0.54%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$180.26 +0.12 (+0.06%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About DaVita Stock (NYSE:DVA)

Advanced

Key Stats

Today's Range
$178.92
$182.69
50-Day Range
$178.25
$240.59
52-Week Range
$101.00
$247.49
Volume
506,552 shs
Average Volume
1.05 million shs
Market Capitalization
$11.49 billion
P/E Ratio
14.74
Dividend Yield
N/A
Price Target
$221.75
Consensus Rating
Hold

Company Overview

DaVita Inc. (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions. The company’s growth has broadened its footprint across the United States and into select international markets, enabling it to serve a diverse patient population. DaVita leverages clinical protocols, integrated care teams and telehealth capabilities to enhance treatment consistency and improve health outcomes.

DaVita places a strong emphasis on clinical quality and patient-centered care, operating under stringent regulatory standards and collaborating closely with physicians, hospitals and payers. The company has introduced various initiatives aimed at reducing hospitalization rates, managing complications and promoting patient independence through home therapies. Its data-driven approach supports continuous improvement in care delivery and resource utilization across its network of facilities.

The company’s leadership team is headed by President and Chief Executive Officer Javier Rodriguez, who oversees DaVita’s strategic direction and operational execution. Under his guidance, DaVita continues to pursue innovations in kidney care, digital health and value-based care models, with the goal of advancing treatment accessibility and driving long-term sustainability in the renal healthcare market.

AI Generated. May Contain Errors.

DaVita Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

DVA MarketRank™: 

DaVita scored higher than 97% of companies evaluated by MarketBeat, and ranked 21st out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DaVita has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    DaVita has a consensus price target of $221.75, representing about 23.1% upside from its current price of $180.14.

  • Amount of Analyst Coverage

    DaVita has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about DaVita's stock forecast and price target.
  • Earnings Growth

    Earnings for DaVita are expected to grow by 18.39% in the coming year, from $14.57 to $17.25 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DaVita is 14.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.94.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DaVita is 14.74, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.27.

  • Price to Earnings Growth Ratio

    DaVita has a PEG Ratio of 0.60. PEG Ratios below 1 indicate that a company could be undervalued.

  • Read more about DaVita's valuation and earnings.
  • Percentage of Shares Shorted

    6.85% of the float of DaVita has been sold short.
  • Short Interest Ratio / Days to Cover

    DaVita has a short interest ratio ("days to cover") of 7.51.
  • Change versus previous month

    Short interest in DaVita has recently decreased by 4.74%, indicating that investor sentiment is improving.
  • Dividend Yield

    DaVita does not currently pay a dividend.

  • Dividend Growth

    DaVita does not have a long track record of dividend growth.

  • News Sentiment

    DaVita has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for DaVita this week, compared to 5 articles on an average week.
  • Search Interest

    10 people have searched for DVA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DaVita insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,210,402.00 in company stock.

  • Percentage Held by Insiders

    1.90% of the stock of DaVita is held by insiders.

  • Percentage Held by Institutions

    90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DaVita's insider trading history.
Receive DVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DVA Stock News Headlines

DaVita (DVA) Q2 2026 Earnings Call Transcript
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
DaVita Target of Unusually Large Options Trading (NYSE:DVA)
See More Headlines

DVA Stock Analysis - Frequently Asked Questions

DaVita's stock was trading at $113.74 at the start of the year. Since then, DVA shares have increased by 58.4% and is now trading at $180.14.

DaVita Inc. (NYSE:DVA) released its quarterly earnings results on Tuesday, August, 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.88 by $0.14. The company's revenue for the quarter was up 5.2% on a year-over-year basis.
Read the conference call transcript
.

DaVita subsidiaries include these companies: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and others.

Top institutional investors of DaVita include BlackRock Inc. (3.86%), Bank of New York Mellon Corp (0.71%), Deutsche Bank AG (0.33%) and Wedge Capital Management L L P NC (0.29%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty and Barbara J Desoer.
View institutional ownership trends
.

Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/04/2026
Today
8/15/2026
Next Earnings (Estimated)
10/28/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NYSE:DVA
CIK
927066
Employees
78,000
Year Founded
1994

Price Target and Rating

High Price Target
$270.00
Low Price Target
$140.00
Potential Upside/Downside
+23.1%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$12.22
Trailing P/E Ratio
14.74
Forward P/E Ratio
12.36
P/E Growth
0.6
Net Income
$746.80 million
Net Margins
6.05%
Pretax Margin
10.48%
Return on Equity
-217.63%
Return on Assets
5.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.47
Quick Ratio
1.41

Sales & Book Value

Annual Sales
$14.01 billion
Price / Sales
0.82
Cash Flow
$21.84 per share
Price / Cash Flow
8.25
Book Value
($7.55) per share
Price / Book
-23.86

Miscellaneous

Outstanding Shares
63,800,000
Free Float
62,588,000
Market Cap
$11.49 billion
Optionable
Optionable
Beta
0.88

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSE:DVA) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners